{"id":"premixed-insulin-analogues","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Hypoglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"These insulins provide both immediate and sustained glucose-lowering effects, mimicking the natural insulin response more closely than traditional insulins.","oneSentence":"Premixed insulin analogues combine rapid-acting and intermediate-acting insulins to manage blood glucose levels in diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:57.032Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06925334","phase":"PHASE4","title":"A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2024-05-20","conditions":"Type 2 Diabetic Patients","enrollment":170},{"nctId":"NCT05545800","phase":"PHASE3","title":"Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2022-09-01","conditions":"Type 2 Diabetes Mellitus","enrollment":78},{"nctId":"NCT01235819","phase":"PHASE4","title":"Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Command Hospital, India","startDate":"2010-11","conditions":"Type 1 Diabetes","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"premixed insulin analogues","genericName":"premixed insulin analogues","companyName":"Xiangya Hospital of Central South University","companyId":"xiangya-hospital-of-central-south-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Premixed insulin analogues are a type of insulin that acts as an agonist to the insulin receptor, a protein target. They are used to treat conditions such as Type 1 Diabetes, Type 2 Diabetic Patients, and Type 2 Diabetes Mellitus, as indicated by clinical trials on ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}